Modified Bis-amide Derivatives as Protease inhibitors for treatment of Covid-19

Bookmark/Download	Download as PDF
Track Code	2021-GHOS-69206
Categories	Chemistry and Chemical Analysis Pharmaceuticals
Keywords	Chemistry and Chemical Analysis Coronavirus COVID-19 Drug Development Medicinal Chemistry Pharmaceuticals Therapeutics
Public Abstract	Researchers at Purdue University have developed a new class of noncovalent functionalized bis-amide inhibitors for treatment of Covid-19. There remains an ongoing global health pandemic which has now affected over 170 million people to date and there is no available therapeutic option. The compounds developed by Purdue researchers in this disclosure are newer modified versions of bis-amide derivatives that have demonstrated potent inhibitory effect on SARS-CoV-2 enzyme, 3CLpro. These inhibitors have been evaluated in immunocytochemical and cellular assays against Covid-19 infections. Advantages: -Potent Covid-19 Antiviral Properties -Improved Drug-Like Features Potential Applications: -Treatment of SARS-CoV-2 -Pharmaceutical Research and Development -Pandemic Control Technology Validation: The bis-amide compounds potently inhibited SARS-CoV-2 in in vitro studies and immunocytochemistry assays.
People	Ghosh, Arun K (Project leader) Mesecar, Andrew D Mitsuya, Hiroaki
Intellectual Property	Application Date Nov 30, 2021 Type PCT-Gov. Funding Country of Filing WO Patent Number (None) Issue Date (None) Application Date Dec 1, 2020 Type Provisional-Gov. Funding Country of Filing United States Patent Number (None) Issue Date (None)
Contact OTC	Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org